🇺🇸 Insulin Lispro-aabc in United States
12 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 12
Most-reported reactions
- Abdominal Pain Upper — 2 reports (16.67%)
- Injection Site Pain — 2 reports (16.67%)
- Abdominal Abscess — 1 report (8.33%)
- Abdominal Discomfort — 1 report (8.33%)
- Abdominal Hernia — 1 report (8.33%)
- Acute Cholecystitis Necrotic — 1 report (8.33%)
- Arthritis — 1 report (8.33%)
- Arthropathy — 1 report (8.33%)
- Blood Glucose Increased — 1 report (8.33%)
- Death — 1 report (8.33%)
Other Diabetes approved in United States
Frequently asked questions
Is Insulin Lispro-aabc approved in United States?
Insulin Lispro-aabc does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Insulin Lispro-aabc in United States?
Eli Lilly and Company is the originator. The local marketing authorisation holder may differ — check the official source linked above.